Save The Date SCIENTIFIC PROGRAM SORTED BY SESSION TYPE

Transcription

1 Save The Date SCIENTIFIC PROGRAM SORTED BY SESSION TYPE

2 25 PARALLEL SESSIONS INCLUDING 4 PROFFERED PAPERS SESSIONS

3 PARALLEL SESSION NUMBER 1 CHAIRMEN: Hans Petter Eikesdal (Norway) and Fausto Roila (Italy) ROOM CAPACITY: Large TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min Endocrine issues in cancer Introduction 2 min Fausto Roila Italy Obesity, diabetes and cancer outcome min Pamela Goodwin Canada Hypothyroidism after radiotherapy min Marianne F Rønjom Denmark Endocrine disorders following treatment with tyrosine kinase inhibitors min Fausto Roila Italy Abstract 25-4-O INCIDENCE OF DIABETES INDUCED BY HIGH-DOSE GLUCOCORTICOID TREATMENT IN CANCER PATIENTS min Helga Schultz Denmark Conclusion 3 min Hans Petter Eikesdal Norway

4 PARALLEL SESSION NUMBER 2 CHAIRMEN: Dorothy Keefe (Australia) and Birgitte Grube (Denmark) ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min Use of E-Health in Supportive Care Introduction 3 min Dorothy Keefe Australia Abstract 04-1-O E-Health is empowered health Nurses experience How can e-health increase adherence to cancer therapy and supportive care? Physicians experience E-health Patients experience WEB-SUPPORTED INFORMATION NEEDS OF CAREGIVERS IN HEMATOLOGIC CANCER min Bodil Westman Sweden min Dorothy Keefe Australia min Jane Pelouchova Czech Republic min G Yigit Turkey Conclusion 2 min Birgitte Grube Denmark

5 PARALLEL SESSION NUMBER 3 CHAIRMEN: Patrick Combrez (Belgium) and Lars Kjeldsen (Denmark) ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min Best Supportive Care in Patients with Haematological Malignancies Introduction 2 min Patrick Crombez Belgium Supportive Care in Haematology 15 min Lars Kjeldsen Denmark General Management of Neutropenic Patients 15 min Patrick Crombez Belgium Nursing Evidence and Controverses in Infection Prevention 15 min Arno Mank The Netherlands Outpatient Bone Marrow Transplantation 15 min William Hogan USA Abstract 08-2-O RISK OF HYPONATRAEMIA IN CANCER PATIENTS TREATED WITH TARGETED THERAPIES: A META-ANALYSIS OF CLINICAL TRIALS min Rossana Berardi Italy Panel discussion 15 min All Conclusion 3 min Lars Kjeldsen Denmark

6 PARALLEL SESSION NUMBER 4 CHAIRMEN: Christoffer Steer (Australia) and Trine Lembrecht Jørgensen (Denmark) ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min Supportive Care in the Elderly Introduction 2 min Trine Lembrecht Jørgensen Denmark Is Cancer Symptom Control Any Different in Older Adult Cancer Patients? min Aminah Jatoi USA Pain control in the elderly min Eduardo Bruera USA Abstract 07-1-O Abstract 07-2-O Nursing Facilities and Cancer Supportive Care: Providing Best Practices Clinical Services To Older Adult Cancer Patients INPUT OF A PHARMACIST-LED MEDICATION EVALUATION IN THE MANAGEMENT OF OLDER PATIENTS WITH CANCER CHARLSON COMORBIDITY INDEX AS A PREDICTOR OF OVERALL SURVIVAL FOR PATIENTS WITH EARLY STAGE NSCLC? min Bente Appel Esbensen Denmark min Myriam Aitichou France min Stefan S Jeppesen Denmark Chairman s conclusion 2 min Christoffer Steer Australia

7 PROFFERED PAPERS - PARALLEL SESSION NUMBER 5 CHAIRMEN: Gilles Freyer (France) and Svend Ottesen (Denmark) ROOM CAPACITY: Medium TIME: Friday 09:00-10:30 DURATION OF SESSION: 90 min Psychooncology and Quality of Life Introduction 1 min Svend Ottesen Denmark 18-1-O 18-2-O 18-3-O 18-4-O 18-5-O 22-1-O 22-2-O 22-3-O CANCER CAREGIVER QUALITY OF LIFE: NEED FOR TARGETED INTERVENTION EXPECTATION EFFECTS IN ENDOCRINE TREATMENT OF BREAST CANCER: A TWO-YEAR PROSPECTIVE CLINICAL COHORT STUDY ESTROGEN RECEPTOR ALPHA (ESR1) GENETIC POLYMORPHISMS AND THE RISK OF CHEMOTHERAPY-ASSOCIATED COGNITIVE IMPAIRMENT IN EARLY-STAGE BREAST CANCER (ESBC) PATIENTS RELATIONSHIP BETWEEN SUBJECTIVE AND ACTIGRAPHY-MEASURED SLEEP IN 237 PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC) THE CONTRIBUTION OF INFORMAL CAREGIVERS IN CANCER CARE, AND PATIENT FACTORS ASSOCIATED WITH CAREGIVER OUTCOMES QUALITY OF LIFE IN ELDERLY/FRAIL PATIENTS WITH GLIOBLASTOMA MULTIFORME: RESULTS OF THE IAEA RANDOMIZED PHASE III STUDY COMPARING SHORT AND STANDARD COURSE OF RADIOTHERAPY VALIDATION OF THE EORTC QLQ-INFO 25 QUESTIONNAIRE IN LEBANESE CANCER PATIENTS: REVEALING A STATE OF BLISSFUL IGNORANCE? CONFLICT, PARENT DISTRESS, FAMILY STRAIN AND HEALTH-RELATED SYMPTOMS IN LONG-TERM SURVIVORS OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) min Maria Lapid USA min Yvonne Nestoriuc Germany Young Investigator Winner min Terence Ng Singapore Outstanding Young Investigator min Oxana Palesh USA min Anna Ugalde Australia min Elena Fidarova Austria min Samer Tabchi Lebanon min I-Chan Huang USA Conclusion 1 min Gilles Freyer France

8 PARALLEL SESSION NUMBER 6 CHAIRMEN: Marianne Ewertz (Denmark) and Michael Ewer (USA) ROOM CAPACITY: Large TIME: Friday 14:30-16:00 DURATION OF SESSION: 90 min Cancer Therapy-Induced Cardio- Pulmonary Toxicity Introduction 1 min Marianne Ewertz Denmark Cardiotoxicity induced by chemotherapy and targeted therapy min Michael Ewer USA Abstract 26-5-O Abstract 24-6-O Pulmonary toxicity induced by chemotherapy and targeted agents PRIMARY VERSUS SECONDARY CARDIOTOXICITY OF ANTI-CANCER TREATMENT: A DISTINCTION WITH BROAD IMPLICATIONS RISK OF CARDIOVASCULAR DISEASE AMONG CANCER SURVIVORS AND AGE- AND GENDER-MATCHED CONTROLS min Richard Gralla USA min Michael Ewer USA min Dounya Schoormans The Netherlands Conclusion 1 min Marianne Ewert Denmark

9 PARALLEL SESSION NUMBER 7 CHAIRMEN: Siri Beier Jensen (Denmark) and Deborah P. Saunders (Canada) ROOM CAPACITY: Medium TIME: Friday 14:30-16:00 DURATION OF SESSION: 90 min Oral Care in Head and Neck Cancer Introduction 2 min Siri Beier Jensen Denmark Translating MASCC/ISOO research into patient-centered care: Multidisciplinary phased oral care for patients undergoing head and neck radiation min Deborah P. Saunders Canada Focus on taste disturbances min Anna Boltong Australia Focus on nutrition min Harriet Jager-Wittenaar The Netherlands Abstract 15-1-O Abstract 15-2-O STIMULATED RESIDUAL SALIVARY GLAND FUNCTION IS CORRELATED TO MEAN RADIATION DOSE DELIVERED TO THE MAJOR SALIVARY GLANDS DURING RADIOTHERAPY FOR HEAD AND NECK CANCER ORAL AND DENTAL STATUS IN LONG- TERM SURVIVORS OF ALLOGENEIC HSCT PERFORMED IN CHILDHOOD, ADOLESCENTS OR YOUNG ADULTHOOD -PRELIMINARY RESULTS min Ruta Zukauskaite Denmark min Kristine Eidal Tanem Norway Concluding remarks 2 min Deborah P. Saunders Canada

10 PARALLEL SESSION NUMBER 8 Joint session FSK, EONS and MASCC CHAIRMEN: Andreas Charalambous (Cyprus) and Alex Molassiotis (Hong Kong) ROOM CAPACITY: Large TIME: Friday 14:30-16:00 DURATION OF SESSION: 90 min Complementary and Alternative Medicine in Cancer Care Introduction 3 min Alex Molassiotis Hong Kong CAM in Cancer Care: New data call for mind shifting? 20 min Andreas Charalambous Cyprus What is the evidence of CAM in cancer patients 20 min Helle Johannessen Denmark Clinical Use of CAM in Cancer Patients 20 min Alex Molassiotis Hong Kong Abstract 04-2-O COMPLEMENTARY MEDICINE EDUCATION FOR ONCOLOGY PROFESSIONALS IN ALBERTA: EVALUATION OF AN ONLINE PROGRAM min Gregory Levin Canada Young Investigator Winner Discussion 15 min Conclusion 2 min Andreas Charalambous Cyprus

11 PARALLEL SESSION NUMBER 9 CHAIRMEN: Jean Jacques Body (Belgium) and Carina Ørts Christensen (Denmark) ROOM CAPACITY: Medium TIME: Friday 14:30-16:00 DURATION OF SESSION: 90 min Bone Health Introduction 1 min Carina Ørts Christensen Denmark Prevention of osteoporosis in cancer patients 15 min Jean Jacques Body Belgium Bone metastases: what is new and what is targeted? 15 min Matti S. Aapro Switzerland Recognition and management of osteonecrosis of the jaw 15 min Cesar Migliorati USA Abstract 01-1-O Abstract 01-2-O Abstract 01-3-O TREATMENT AND PREVENTION OF OSTEONECROSIS OF THE JAW ASSOCIATED WITH MEDICATION: PALLIATIVE SURGICAL INTENT IN THE TREATMENT OF BONE SARCOMAS: A MIDTERM REVIEW FROM A RESOURCE CHALLENGED ENVIRONMENT RISK OF OSTEOPOROSIS SUBSEQUENT TO CHEMOTHERAPY FOR EARLY- STAGE BREAST CANCER min E. Papadopoulou Greece min SA Khan India min Carina Ørts Christensen Denmark Optimising Bone Health: Discussion 12 min All Conclusion 2 min Jean Jacques Body Belgium

12 PROFFERED PAPERS - PARALLEL SESSION 10 CHAIRMEN: Andrea Cheville (USA) and Julie Silver (USA) ROOM CAPACITY: Medium Time: Friday :00 DURATION OF SESSION: 90 min Rehabilitation and survivorship Introduction 1 min Andrea Cheville USA 24-1-O 24-5-O 24-2-O 24-3-O 23-7-O 23-3-O 23-4-O 23-6-O COMPARING THE COSTS OF THREE PROSTATE CANCER FOLLOW-UP STRATEGIES: A COST-MINIMISATION ANALYSIS IMPLEMENTATION OF THE PROSTATE CANCER SUPPORTIVE CARE (PCSC) PROGRAM, A COMPREHENSIVE APPROACH FOR MEN WITH PROSTATE CANCER (PC) AND THEIR PARTNERS QUALITY OF LIFE, HEALTH AND PERSONAL WELLBEING UP TO TWO YEARS FOLLOWING CURATIVE INTENT COLORECTAL CANCER SURGERY: RESULTS FROM THE UK COLORECTAL WELLBEING (CREW) STUDY PREOPERATIVE ANAEMIA AND BLOOD-TRANSFUSION AS PROGNOSTIC FACTORS FOR MORTALITY IN COLORECTAL CANCER - A SWEDISH COHORT STUDY IMPROVING ADHERENCE TO CANCER TREATMENT BY ADDRESSING QUALIT LIFE IN PATIENTS WITH ADVANCED GASTROINTESTINAL CANCERS IMPACT AND FEASIBILITY OF AN EXERCISE PROGRAM DURING CHEMO- RADIOTHERAPY IN HEAD AND NECK CANCER SURVIVORS:A RANDOMIZED CONTROLLED TRIAL INSULIN-LIKE GROWTH FACTORS ARE MODULATED BY EXERCISE IN BREAST CANCER SURVIVORS: A META-ANALYSIS WITH META- REGRESSION SEXUALITY AND SEXUAL FUNCTION ONE YEAR AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION min Alison Pearce Jamaica Young Investigator Winner min S L Goldenberg Canada min Claire Foster United Kingdom min Malin Mörner Sweden min J Basford Canada min Stephen Samuel India Young Investigator Winner min Jose F M Echávez Colombia min Kristina Nørskov Denmark Conclusion 1 min Julie Silver USA

13 PARALLEL SESSION NUMBER 11 CHAIRMEN: Mario Dicato (Luxembourg) and Bernardo Rapoport (South Africa) ROOM CAPACITY: Large TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min Bone marrow toxicity Introduction 2 min Mario Dicato Luxembourg Anemia in cancer: an update of the use of iron, EPO and activin receptor antagonists min Matti Aapro Switzerland Febrile neutropenia: an update of outpatient management of low risk patients min Jean Klastersky Belgium Febrile neutropenia: an update of management of high risk - stem cell transplantation patients min William Hogan USA Thrombocytopenia and thrombopoietin min Mario Dicato Luxembourg Abstract 26-2-O Abstract 13-1-O INTRAVENOUS IRON ISOMALTOSIDE 1000 (MONOFER ) AS MONO THERAPY IN COMPARISON WITH ORAL IRON SULPHATE IN PATIENTS WITH NON-MYELOID MALIGNANCIES ASSOCIATED WITH CHEMOTHERAPY INDUCED ANAEMIA (CIA) BIOSIMILAR FILGRASTIM AND CHEMOTHERAPY-INDUCED NEUTROPENIA: OVERALL RESULTS OF THE NEXT STUDY min G Birgegård Sweden min D Kamioner France Conclusion 3 min Bernardo Rapoport South Africa

14 PARALLEL SESSION NUMBER 12 CHAIRMEN: Mario Lacouture (USA) and Inge Marie Svane (Denmark) ROOM CAPACITY: medium TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min Novel Therapies and Best Supportive Care in Cutaneous Malignancies Introduction 5 min Mario Lacouture USA Efficacy of agents targeting the BRAF/MEK pathway 15 min Peter Arne Gerber Germany Discussion 5 min Efficacy of immune checkpoint inhibitors 15 min Inge Marie Svane Denmark Discussion Systemic toxicities from BRAF/MEK pathway and Immune check point inhibitors Discussion Dermatologic toxicities from BRAF/MEK pathway and Immune check point inhibitors Discussion 5 min 15 min Vincent Sibaud France 5 min 15 min Mario Lacouture USA 5 min Conclusion 5 min Inge Marie Svane Denmark

15 PARALLEL SESSION NUMBER 13 CHAIRMEN: Petra Feyer (Germany) and Marianne Ewertz (Denmark) ROOM CAPACITY: Medium TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min Radiotherapy-induced Late Toxicities in Cancer Survivors Introduction 2 min Marianne Ewertz Denmark Late Complications Induced by Radiotherapy in Head and Neck Cancer Patients min Petra Feyer Germany Carditoxicity induced by radiotherapy min Sarah C Darby United Kingdom Gastrointestinal late complications of radiotherapy min Ann Muls United Kingdom Abstract 25-3-O COMPARISON OF BENEFITS, SAFETY OF 8% VERSUS 4% FORMALIN FOR TREATMENT OF CHRONIC HEMORRHAGIC RADIATION PROCTITIS IN PATIENTS OF CERVICAL CARCINOMA: A RANDOMIZED CONTROLLED TRIAL min Mukesh Singhal India Conclusion 3 min Petra Feyer Germany

16 PROFFERED PAPERS - PARALLEL SESSION 14 CHAIRMEN: Paul Hesketh (USA) and Rajesh Lalla (USA) ROOM CAPACITY: Medium TIME: Friday 17:45-19:15 DURATION OF SESSION: 90 min Gastro-intestinal toxicity Introduction 1 min Paul Hesketh USA 11-2-O 11-3-O 11-4-O 11-5-O 11-6-O 10-3-O 10-4-O 10-5-O ANTIEMESIS PROPHYLAXIS AMONG BREAST CANCER (BC) PATIENTS RECEIVING ANTHRACYLINE-BASED CHEMOTHERAPY: A POPULATION- BASED STUDY. EFFICACY AND SAFETY OF ROLAPITANT FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF HIGHLY- OR MODERATELY EMETOGENIC CHEMOTHERAPY (HEC; MEC) ROLE OF OLANZAPINE IN CHEMOTHERAPY INDUCED NAUSEA AND VOMITING ON PLATINUM BASED CHEMOTHERAPY PATIENTS; A RANDOMIZED CONTROLLED STUDY THE ORAL ADMINISTRATION OF THE BRAIN PENETRATING GHRELIN AGONIST, HM01, ANTAGONIZES CISPLATIN-INDUCED EMESIS IN SUNCUS MURINUS (HOUSE MUSK SHREW) SINGLE- VERSUS MULTIPLE-DAY CORTICOSTEROID DOSING FOR DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING TIGHT JUNCTION DISRUPTION IS SEEN IN THE ORAL CAVITY OF PATIENTS RECEIVING STANDARD DOSE CHEMOTHERAPY. DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED ASSESSMENT TOOL FOR SYSTEMIC THERAPY-INDUCED DIARRHEA ASSOCIATION BETWEEN ORAL MICROBIOME AND MUCOSITIS IN HEMATOPOIETIC STEM CELL TRANSPLANT SUBJECTS min Mariana Chavez USA Mac Gregor Young Investigator Winner min Bernardo Rapoport South Africa min Sandip Mukhopadhyay India min John Rudd Hong Kong min Pamela Ng Canada min Hannah Wardill Australia min Michelle Lui Canada min Farah Mougeot USA Conclusion 1 min Rajesh Lalla USA

17 PARALLEL SESSION NUMBER 15 CHAIRMEN: Matti Aapro (Switzerland) and Didier Kamioner (France) ROOM CAPACITY: Medium TIME: Saturday 10:30-12:00 DURATION OF SESSION: 90 min MASCC AFSOS Symposium Introduction 2 min Matti Aapro Switzerland Pharmacist in Cancer Care Unit; A Role for Quality of Care? Discussion Back Home: Evidence for Supportive Network; how, when and for who? Discussion 10 min Jean Baptiste Rey France 5 min 10 min Manon Lemonde Canada 5 min Mucositus Guidelines : An Update 10 min RJ Bensadoun France Discussion Breathlessness at the Palliative Time : From Guidelines to Practice Discussion 5 min 10 min Claudia Mazzocato Switzerland 5 min European Supportive Care Associations in MASCC: from AFSOS to NICSO (Roundtable discussion) 25 min Petra Feyer Carla Ripamonti Ivan Krakowski Germany Italy France Conclusion 3 min Didier Kamioner France

18 PARALLEL SESSION NUMBER 16 CHAIRMEN: Karin Olson (Canada) and Eric van Muilekom ROOM CAPACITY: Medium TIME: Saturday 10:30-12:00 DURATION OF SESSION: 90 min Fatigue Introduction 2 min Eric van Muilekom The Netherlands How do we define fatigue and what is new? min Karin Olson Canada Cancer-related sleep disturbances min Poul Jennum Denmark Compassion fatigue: How to deal with it? min Eric van Muilekom The Netherlands Fatigue in advanced cancer min Andreas Charalambous Cyprus Abstract 06-1-O RANDOMIZED TRIAL OF YOGA VERSUS STRENGTHENING EXERCISES IN BREAST CANCER SURVIVORS WITH PERSISTENT FATIGUE min Daniela Stan USA Conclusion 3 min Karin Olson Canada

19 PARALLEL SESSION NUMBER 17 CHAIRMEN: Charles Loprinzi (USA) and Lise Eckhoff (Denmark) ROOM CAPACITY: Medium TIME: Saturday 10:30-12:00 DURATION OF SESSION: 90 min Neurological Complications Introduction 1 min Charles Loprinzi USA Genomic risks for developing CIPN min Lise Eckhoff Denmark Treatment of CIPN min Charles Loprinzi USA Evidence-based caring for patients with CIPN min Anita Margulies Switzerland Abstract 12-1-O Abstract 12-2-O CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS: INFLUENCE ON QUALITY OF LIFE AND VALIDATION OF A QUESTIONNAIRE FOR DAILY CLINICAL PRACTICE CAN PREGABALIN PREVENT PACLITAXEL-ASSOCIATED NEUROPATHY? A PILOT TRIAL min Antoinetta Beijers The Netherlands min Shivani Shinde USA Conclusion 1 min Lise Eckhoff Denmark

20 PARALLEL SESSION NUMBER 18 joint session IASLC/MASCC CHAIRMEN: Richard Gralla (USA) and tbd ROOM CAPACITY: Large TIME: Saturday :00 DURATION OF SESSION: 90 min Supportive Care in Lung Cancer Introduction 3 min Richard Gralla USA Management of NSCLC state of the art 20 min tbd Dyspnea magnitude of the problem and management 15 min Sam Ahmedzai United Kingdom New options in the management of hyponatremia 10 min Mellar Davis USA Quality of life in lung cancer 15 min Richard Gralla USA Abstract 24-4-O OVERALL SURVIVAL AFTER PALLIATIVE THORACIC RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER NOT SUITABLE FOR CURATIVE INTENDED TREATMENT min Olfred Hansen Denmark How to optimize supportive care in lung cancer? 15 min Round table discussion All Conclusion 2 min tbd

21 PARALLEL SESSION NUMBER 19 CHAIRMEN: Sebastiano Mercadante (Italy) and Sam Ahmedzai (United Kingdom) ROOM CAPACITY: Large TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min Cancer Pain Opioids and Beyond Introduction 2 min Sebastiano Mercadante Italy Neuronal mechanisms and targeted therapy of bone cancer pain min Sam Ahmedzai United Kingdom Understanding visceral pain - origins and treatments min Sebastiano Mercadante Italy Abstract 03-1-O Abstract 03-2-O Cancer pain at the end of life rational and realistic management choices EFFICACY, SAFETY, AND TOLERABILITY OF FULRANUMAB AS ADJUNCTIVE THERAPY FOR CANCER-RELATED PAIN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY COMPARISON OF UPPER AND LOWER EXTREMITY CHARACTERIZATIONS OF CHEMOTHERAPY-INDUCED NEUROPATHY (CIN) USING PATIENT REPORTED OUTCOME MEASURES Conclusion min Eduardo Bruera USA min Neal Slatkin USA min Christine Miakowski USA 3 min Sam Ahmedzai United Kingdom

22 PARALLEL SESSION NUMBER 20 CHAIRMEN: Mario Lacouture (USA) and Jennifer Choi (USA) ROOM CAPACITY: medium TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min Skin toxicity Introduction 5 min Jennifer Choi USA Assessment of skin toxicity 20 min Christine Boers-Doets NED Case 1 (chemotherapy) 5 min Mario Lacouture USA Discussion 10 min Moderator: Jennifer Choi USA State of the art: chemotherapy-induced skin toxicity 15 min Mario Lacouture USA Case 2 (targeted therapy) 5 min Jennifer Choi USA Discussion 10 min Moderator: Mario Lacouture USA State of the art: targeted therapy-induced skin toxicity 15 min Jennifer Choi USA Conclusion 5 min Mario Lacouture USA

23 PARALLEL SESSION NUMBER 21 CHAIRMEN: Charles Loprinzi (USA) and Tom Møller (Denmark) ROOM CAPACITY: Large TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min Supportive Care in Breast Cancer the Significance of Life Style Introduction 1 min Charles Loprinzi Loprinzi USA Use of Exercise in Patients with Breast Cancer 15 min Tom Møller Denmark Q & A 5 min Healthy Diet and Lifestyle for Breast Cancer Patients 15 min Christina Lacerda Portugal Abstract 26-3-O Abstract 23-5-O Abstract 09-1-O Q & A Smoking as an Independent Risk Factor for Radiotherapy- Induced Skin Reactions in Breast Cancer Q & A RACIAL DIFFERENCES IN EARLY SYMPTOM MANAGEMENT, HOSPICE USE, AND INTENSITY OF END-OF-LIFE CARE AMONG ELDERLY WOMEN WITH BREAST CANCER THE EFFECT OF EXERCISE TRAINING ON MEDIATORS OF TUMOUR PROGRESSION IN BREAST CANCER SURVIVORS: A META-ANALYSIS STANDARDIZING LYMPHEDEMA ASSESSMENT PRACTICES: A QUALITY IMPROVEMENT INITIATIVE IN ALBERTA CANADA 4 min 15 min Lena Sharp Sweden 4 min min Devon Check USA min Jose F M Echávez Colombia min Margaret McNeely Canada Conclusion 1 min Tom Møller Denmark

24 PARALLEL SESSION NUMBER 22 CHAIRMEN: Richard Gralla (USA) and Jørn Herrstedt (Denmark) ROOM CAPACITY: Large TIME: Saturday 14:45-16:15 DURATION OF SESSION: 90 min Chemotherapy-induced nausea and vomiting Introduction 2 min Jørn Herrstedt Denmark Emetic risk classification of antineoplastic agents min Paul Hesketh USA Use of antiemetics targeting a single receptor min Karin Jordan Germany Use of antiemetics targeting multiple receptors min David Warr Canada Use of antiemetics in chemoradiation min Christina Ruhlmann Denmark Abstract 11-1-O IMPACT AND MANAGEMENT OF CHEMOTHERAPY/ RADIOTHERAPY- INDUCED NAUSEA AND VOMITING AND THE PERCEPTUAL GAP BETWEEN ONCOLOGISTS/ONCOLOGY NURSES AND PATIENTS: A CROSS-SECTIONAL MULTINATIONAL SURVEY min Bahrat Amlani United Kingdom Conclusion 3 min Richard Gralla USA

25 PARALLEL SESSION NUMBER 23 CHAIRMEN: Sharon Elad (USA) Ourania Nicolatou-Galitis (Greece) ROOM CAPACITY: Medium TIME: Saturday 14:45-16:15 DURATION OF SESSION: 90 min Mucositis Introduction 2 min Ourania Nicolatou- Galitis Greece Update on low level laser therapy for oral mucositis min Sharon Elad USA Abstract 10-1-O Abstract 10-2-O Updates on clinical studies of palifermin for oral and gastrointestinal mucositis Stomatitis secondary to targeted anti-cancer agents CLONIDINE MUCOADHESIVE BUCCAL TABLET (CLONIDINE LAURIAD) PREVENTS SEVERE RADIOMUCOSITIS IN HEAD AND NECK CANCER PATIENTS: A PHASE II RANDOMIZED TRIAL EFFECTIVENESS OF LOW-LEVEL LASER THERAPY IN THE PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED ORAL MUCOSITIS IN CHILDREN min Nicole M. A. Blijlevens The Netherlands min Ourania Nicolatou- Greece Galitis min Rene-Jean Bensadoun France min Alessandra Majorana Italy Conclusion 2 min Sharon Elad USA

26 PARALLEL SESSION NUMBER 24 CHAIRMEN: Andrea Cheville (USA) and Ann-Dorthe Olsen Zwisler (Denmark) ROOM CAPACITY: Large TIME: Saturday 14:45-16:15 DURATION OF SESSION: 90 min Rehabilitation Introduction 2 min Andrea Cheville USA Lessons to be learned from rehabilitation of non-cancer patients min Ann-Dorthe Olsen Zwisler Denmark Rehabilitation of older adults with cancer min Christoffer Steer Australia Optimization of Cancer Rehabilitation min Andrea Cheville USA Abstract 23-1-O Abstract 23-2-O PATIENT ACTIVATION THROUGH COUNSELING AND EXERCISE ACUTE LEUKEMIA (PACE-AL) TRIAL A RANDOMIZED CONTROLLED TRIAL THE MEDIATING ROLE OF PERCEIVED DISABILITY IN THE LONG-TERM IMPACT OF ARM MORBIDITY ON BREAST CANCER SURVIVORS' EMOTIONAL WELL-BEING Conclusion min Mary Jarden Denmark min Thomas Hack Canada 1 min Ann-Dorthe Olsen Denmark Zwisler

27 PARALLEL SESSION NUMBER 25 CHAIRMEN: Declan Walsh (Ireland) and Eduardo Bruera (USA) ROOM CAPACITY: Medium TIME: Saturday 14:45-16:15 DURATION OF SESSION: 90 min Nutrition and cancer cachexia Introduction 1 min Declan Walsh Ireland 14-1-O SWALLOW ASSESSMENT IN HEAD AND NECK CANCER PATIENTS TREATED WITH MULTI-MODALITY THERAPY: COMPARISON OVER TIME OF SELF- REPORT, PHYSICAL EXAM FINDINGS AND OBJECTIVE MEASURES (R min M Maddalo Italy CA A1) 14-2-O DIETARY AND EXERCISE INTERVENTIONS TO IMPROVE QUALITY OF LIFE, METABOLIC RISK FACTORS AND ANDROGEN DEFICIENCY SYMPTOMS IN MEN WITH PROSTATE CANCER UNDERGOING ANDROGEN DEPRIVATION THERAPY min L Teleni Australia 14-3-O 14-4-O 02-1-O 02-2-O 02-3-O 02-4-O CANCER MALNUTRITION AND CLINICAL OUTCOMES: RESULTS FROM TWO POINT PREVALENCE STUDIES IN AUSTRALIA min K Marshall Australia EXPLORING POTENTIAL BENEFIT OF EARLIER NUTRITIONAL INTERVENTIONS IN ADULTS WITH UPPER GASTROINTESTINAL CANCER: A RANDOMISED TRIAL min MA Silvers Australia RESULTS FROM ROMANA 1 AND 2: TWO PHASE III TRIALS OF ANAMORELIN ADVANCED min A Abernethy USA NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH CACHEXIA RESULTS FROM ROMANA 3: A SAFETY EXTENSION STUDY OF ANAMORELIN IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS min D Currow Australia WITH CACHEXIA IMPACT OF CANCER CACHEXIA ON THE PHARMACOLOGY AND TOXICITY min OF CHEMOTHERAPY (5-FU, PACLITAXEL) AND THE ORAL TYROSINE F Strasser Switzerland KINASE INHIBITOR ERLOTINIB: A RETROSPECTIVE PILOT STUDY (CAT) VALIDATING ASSESSMENT OF SKELETAL MUSCLE MASS (SMM) AT L1 ON CHEST CT SCAN IN EVALUATING CANCER CACHEXIA (CC) AND min A Recio-Boiles USA SARCOPENIA IN PATIENTS WITH LUNG CANCER Conclusion 1 min Eduardo Bruera USA

28 3 PLENARY SESSIONS

29 PLENARY SESSION NUMBER 1 CHAIRMEN: David Warr (Canada) and Jørn Herrstedt (Denmark) ROOM CAPACITY: Large TIME: Thursday 12:45-13:45 DURATION OF SESSION: 60 min Supportive Care is a Continuum Introduction to session and Einhorn 2 min David Warr Canada Late Toxicities Induced by Anti-Neoplastic Agents; a Half Century Evaluation of Advantages and Challenges 28 min Lawrence H Einhorn USA Introduction Silver 1 min Jørn Herrstedt Denmark The Role of Prehabilitation and Rehabilitation in High-Quality Cancer Care 28 min Julie Silver USA Closure 1 min Jørn Herrstedt Denmark

30 PLENARY SESSION NUMBER 2 CHAIRMEN: David Warr (Canada) and Marianne Ewertz (Denmark) ROOM CAPACITY: Large TIME: Friday 11:00-12:00 DURATION OF SESSION: 60 min Pharmaceutical Supportive Care Introduction to session and Chan 3 min David Warr Canada Steven Grunberg Award Session Pharmacogenomics in Supportive Care 18 min Alexandre Chan Singapore Introduction Lassen 1 min Marianne Ewertz Denmark Unmasking Side Effects from First-in-Man Antineoplastic Medicine 18 min Ulrik Lassen Denmark Introduction Keefe 1 min David Warr Canada New Developments in Personalised Supportive Care Medicine 18 min Dorothy Keefe Australia Closure 1 min Marianne Ewertz Denmark

31 PLENARY SESSION NUMBER 3 CHAIRMEN: Lawrence H Einhorn (USA) and Declan Walsh (IRL) ROOM CAPACITY: Large TIME: Saturday 09:00-10:00 DURATION OF SESSION: 60 min The Oncologic Tsunami Introduction to session and Gosney 2 min Declan Walsh Ireland Older Cancer Patients Survive are we prepared? 28 min Margot A Gosney United Kingdom Introduction Olver 2 min Lawrence H Einhorn USA Reality of Supportive Care in the Developing World 28 min Ian Olver Australia Closure 1 min Declan Walsh Ireland

32 3 PRO ET CON SESSIONS

33 PRO ET CON SESSION NUMBER 1 CHAIRMEN: Alex Chan (Singapore) ROOM CAPACITY: Medium TIME: Thursday 12:45-13:45 DURATION OF SESSION: 60 min Antithrombotic agents for every patient with incurable cancer? Introduction and voting 5 min Alex Chan Singapore PRO 20 min Mario Dicato Luxemburg CON 20 min Florian Strasser Switzerland Discussion and new voting 15 min Alex Chan Singapore

34 PRO ET CON SESSION NUMBER 2 CHAIRMAN: Sam Ahmedzai (United Kingdom) ROOM CAPACITY: Large TIME: Thursday 16:15-17:15 DURATION OF SESSION: 60 min Euthanasia, assisted dying Introduction and voting 5 min Sam Ahmedzai United Kingdom PRO 20 min Dominique Lossignol Belgium CON 20 min Gilles Freyer France Discussion and new voting 15 min Sam Ahmedzai United Kingdom

35 PRO ET CON SESSION NUMBER 3 CHAIRMAN: Declan Walsh (Ireland) ROOM CAPACITY: Large TIME: Friday 17:45-18:45 DURATION OF SESSION: 60 min Parenteral nutrition in advanced cancer Introduction and voting 5 min Declan Walsh Ireland PRO 20 min Florian Strassser Switzerland CON 20 min Eduardo Bruera USA Discussion and new voting 15 min Declan Walsh Ireland

36 7 CHALLENGE YOUR EXPERT SESSIONS

37 CHALLENGE YOUR EXPERT SESSION NUMBER 1 CHAIRMAN: Fausto Roila (Italy) EXPERT: Mellar Davis (USA) ROOM CAPACITY: Medium TIME: Thursday 16:15-17:15 DURATION OF SESSION: 45 min Management of nausea and vomiting in advanced cancer Introduction 3 min Fausto Roila Italy State of the art lecture 25 min Mellar Davis USA Discussion 15 min All Conclusion 2 min Fausto Roila Italy

38 CHALLENGE YOUR EXPERT SESSION NUMBER 2 CHAIRMAN: Eduardo Bruera (USA) EXPERT: Declan Walsh (Ireland) ROOM CAPACITY: Medium TIME: Thursday 16:15-17:15 DURATION OF SESSION: 45 min Use of cannabinoids in cancer therapy and supportive care Introduction 3 min Eduardo Bruera USA State of the art lecture 25 min Declan Walsh Ireland Discussion 15 min All Conclusion 2 min Eduardo Bruera USA

39 CHALLENGE YOUR EXPERT SESSION NUMBER 3 CHAIRMAN: Svend Saalbach Ottesen (Denmark) EXPERT: Eduardo Bruera (USA) ROOM CAPACITY: Medium TIME: Saturday 08:00-08:45 DURATION OF SESSION: 45 min Management of patients with delirium Introduction 3 min Svend Saalbach Ottesen Denmark State of the art lecture 25 min Eduardo Bruera USA Discussion 15 min All Conclusion 2 min Svend Saalbach Ottesen Denmark

40 CHALLENGE YOUR EXPERT SESSION NUMBER 4 CHAIRMAN: Aminah Jatoi (USA) EXPERT: Florian Strasser (Switzerland) ROOM CAPACITY: Medium TIME: Saturday 08:00-08:45 DURATION OF SESSION: 45 min Nutrition and Cancer Cachexia Introduction 3 min Aminah Jatoi USA State of the art lecture 25 min Florian Strasser Switzerland Discussion 15 min All Conclusion 2 min Aminah Jatoi USA

41 CHALLENGE YOUR EXPERT SESSION NUMBER 5 CHAIRMAN: Mellar Davis (USA) EXPERT: Mario Dicato (Luxembourg) ROOM CAPACITY: Medium TIME: Saturday 08:00-08:45 DURATION OF SESSION: 45 min Cancer and Thrombosis Introduction 3 min Mellar Davis USA State of the art lecture 25 min Mario Dicato Luxembourg Discussion 15 min All Conclusion 2 min Mellar Davis USA

42 CHALLENGE YOUR EXPERT SESSION NUMBER 6 CHAIRMAN: Bernardo Rapoport (South Africa) EXPERT: Jean Klastersky (Belgium) ROOM CAPACITY: Medium TIME: Saturday 08:00-08:45 DURATION OF SESSION: 45 min Fever of Unknown Origin Introduction 3 min Bernardo Rapoport South Africa State of the art lecture 25 min Jean Klastersky Belgium Discussion 15 min All Conclusion 2 min Bernardo Rapoport South Africa

43 CHALLENGE YOUR EXPERTS SESSION NUMBER 7 CHAIRMAN: Fred Ashbury (Canada) EXPERTS: Fred Ashbury (Canada), Paul Hesketh (USA) and Ian Olver (Australia) ROOM CAPACITY: Medium TIME: Saturday 13:00-14:30 DURATION OF SESSION: 90 min How to prepare and submit a paper for Supportive Care in Cancer Introduction 5 min Fred Ashbury Canada The editors view 10 min Fred Ashbury Canada The authors view 20 min Paul Hesketh USA The reviewers view 20 min Ian Olver Australia Discussion 30 min All Conclusion 5 min Fred Ashbury Canada

44 6 PROFFERED PAPERS AND EXPERTS OPINIONS SESSIONS

45 PROFFERED PAPERS AND EXPERTS OPINIONS 1 CHAIRMEN AND EXPERTS: Dorothy Keefe (Australia) and Mario Lacouture (USA) ROOM CAPACITY: Medium TIME: Thursday :15 DURATION OF SESSION: 60 min Toxicity of targeted agents Introduction to session and to toxicity of targeted agents 2 min Dorothy Keefe Australia Abstract 25-1-O META-ANALYSIS: HYPERTENSION RISK IN SELECTED TARGETED AGENTS 8 min Carmelita Escalante USA Abstract 26-7-O ANTIANGIOGENIC-SPECIFIC ADVERSE EVENTS (AES) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH NINTEDANIB (N) AND DOCETAXEL (D) 8 min Anders Mellemgaard Denmark Expert opinion abstracts 25-1-O and 26-5-O 12 min Dorothy Keefe Australia Skin toxicity Introduction skin toxicity 1 min Mario Lacouture USA Abstract 20-1-O Abstract 20-2-O LOW LEVEL LASER THERAPY FOR THE MANAGEMENT OF RADIATION DERMATITIS: FINAL RESULTS OF THE DERMIS TRIAL, A PILOT STUDY IN BREAST CANCER PATIENTS PALMAR PLANTAR ERYTHRODYSESTHESIA PREVENTION WITH ATORVASTATIN AND POLYPRENOL 8 min Jeroen Mebis Belgium 1 min Sergejs Kuznecovs Latvia Expert opinion abstracts 20-1-O and 20-2-O 12 min Mario Lacouture USA Closure 1 min Mario Lacouture USA

46 PROFFERED PAPERS AND EXPERTS OPINIONS 2 CHAIRMEN AND EXPERTS: Fausto Roila (Italy) and Charles Loprinzi (USA) ROOM CAPACITY: Medium TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min Bone complications and chemotherapy-induced nausea and vomiting Abstract 27-3-O LBA Abstract 27-2-O LBA Introduction 1 min Fausto Roila Italy PREVALENCE OF LOW BONE MASS AND OSTEOPOROSIS IN WOMEN DIAGNOSED WITH GYNECOLOGIC CANCER A RANDOMIZED, PHASE 3, DOUBLE-BLIND STUDY OF INTRAVENOUS FOSAPREPITANT AS A SINGLE DOSE FOR PREVENTING HEMOTHERAPY- INDUCED NAUSEA AND VOMITING ASSOCIATED WITH MODERATELY EMETOGENIC CHEMOTHERAPY 8 min Beatrice Edwards USA 8 min Bernardo Rapoport South Africa Expert opinion abstracts 27-3-O and 27-2-O 12 min Fausto Roila Italy Neurological complications Introduction 1 min Charles Loprinzi USA Abstract 27-1-O LBA PREVENTION OF NEUROPATHY USING CALMANGAFODIPIR (PLEDOX ): RESULTS FROM A PHASE I STUDY AND A PLACEBO-CONTROLLED RANDOMIZED STUDY (PLIANT) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) 8 min Bengt Glimelius Sweden Expert opinion abstract 27-1-O 6 min Charles Loprinzi USA Closure 1 min Charles Loprinzi USA

47 PROFFERED PAPERS AND EXPERTS OPINIONS 3 CHAIRMEN AND EXPERTS: Florian Strasser (Switzerland) and Alexander Chan (Singapore) ROOM CAPACITY: Small TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min Palliative Care Introduction palliative care 1 min Florian Strasser Switzerland Abstract 17-1-O Abstract 05-1-O A DIAGNOSTIC MODEL FOR IMPENDING DEATH IN PATIENTS WITH ADVANCED CANCER PROGNOSTIC EVALUATION IN PALLIATIVE CARE: FINAL RESULTS FROM A PROSPECTIVE COHORT STUDY 8 min David Hui USA 8 min Paola Ermacora Italy Expert opinion abstracts 17-1-O and 05-1-O 12 min Florian Strasser Switzerland Abstract 17-2-O CHEMICAL COMPATIBILITY/STABILITY OF COMMONLY USED DRUG COMBINATIONS ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INFUSIONS FOR END OF LIFE CARE 8 min Andrew Dickman United Kingdom Expert opinion abstract 17-2-O 7 min Alexander Chan Singapore Closure 1 min Alexander Chan Singapore

48 PROFFERED PAPERS AND EXPERTS OPINIONS 4 CHAIRMEN AND EXPERTS: Rajesh Lalla (USA) and Alexis Molassiotis (Hong Kong) ROOM CAPACITY: Small TIME: Friday 16:30-17:30 DURATION OF SESSION: 60 min Evidence-based guidelines Introduction to session and to development of guidelines 2 min Rajesh Lalla USA Abstract 19-1-O Abstract 25-2-O DEVELOPING AN EVIDENCE-BASED GUIDELINE FOR MANAGEMENT OF DYSPNEA IN CANCER PATIENTS: DESCRIPTION OF MASCC RESPIRATORY STUDY GROUP TASK PROACTIVE APPROACH: DEVELOPING AND IMPLEMENTING GUIDELINES FOR TREATING PATIENTS WITH ORALLY-ADMINISTERED ANTI-CANCER DRUGS (OAACD) IN THE HOME-CARE SETTING: EXPERIENCE OF A COMPREHENSIVE CANCER CENTER 8 min Sam Ahmedzai United Kingdom 8 min Tal Granot Israel Expert opinion abstracts 19-1-O and 25-2-O 12 min Rajesh Lalla USA Education Introduction education 1 min Alex Molassiotis Hong Kong Abstract 04-3-O Abstract 04-4-O ONCOLOGY NURSING SOCIETY (ONS) PUTTING EVIDENCE INTO PRACTICE (PEP): SYNTHESIS OF EVIDENCE BASED INTERVENTIONS FOR ADHERENCE TO ORAL AGENTS FOR CANCER STRENGTHS, WEAKNESSES AND AREAS FOR IMPROVEMENTS: A COMPARATIVE SURVEY OF UNDERGRADUATE PALLIATIVE CARE (PC) EDUCATION ACROSS ALL UK MEDICAL SCHOOLS (MS) 8 min Cynthia Rittenberg USA 8 min Steven Walker United Kingdom Expert opinion abstracts 04-2-O and 04-3-O 12 min Alex Molassiotis Hong Kong Closure 1 min Alex Molassiotis USA

49 PROFFERED PAPERS AND EXPERTS OPINIONS 5 CHAIRMEN AND EXPERTS: Ian Olver (Australia) and Mellar Davis (USA) ROOM CAPACITY: Medium DURATION OF SESSION: 60 min TIME: Friday 16:30-17:30 Palliative care Introduction to session and to palliative care 2 min Ian Olver Australia Abstract 17-3-O Abstract 17-4-O EXPLORING THE COMPLEXITIES OF CAREGIVER QUALITY OF LIFE: QUALITATIVE RESULTS FROM A TRIAL OF EARLY PALLIATIVE CARE DIFFERENCES IN ATTITUDES AND BELIEFS TOWARD CANCER TREATMENTS AT THE END-OF-LIFE BETWEEN HEMATOLOGIC AND SOLID TUMOR ONCOLOGY SPECIALISTS Julie McDonald Canada 8 min Young Investigator Winner 8 min David Hui USA Expert opinion abstracts 17-3-O and 17-4-O 12 min Ian Olver Australia Abstract 17-5-O Abstract 17-6-O THE FREQUENCY, CHARACTERISTICS AND OUTCOMES AMONG CANCER PATIENTS WITH DELIRIUM ADMITTED TO AN ACUTE PALLIATIVE CARE UNIT (APCU) SLEEP DISTURBANCE CONTRIBUTES TO CRF IN CANCER PATIENTS WITH ACTIVE DISEASE 8 min Maxine de la Cruz USA 8 min Diwakar Balachandran USA Expert opinion abstracts 04-2-O and 04-3-O 12 min Mellar Davis USA Closure 2 min Mellar Davis USA

50 PROFFERED PAPERS AND EXPERTS OPINIONS 6 CHAIRMEN AND EXPERTS: Aminah Jatoi (USA) and Sam Ahmedzai (United Kingdom) ROOM CAPACITY: Medium TIME: Friday 16:30-17:30 DURATION OF SESSION: 60 min Pediatrics Introduction to session and to pediatrics 2 min Aminah Jatoi USA Abstract 16-1-O Abstract 16-2-O DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES FOR SUPPORTIVE CARE IN CHILDHOOD CANCER IN THE NETHERLANDS CURRENT VARIATIONS IN SUPPORTIVE CARE PRACTICE TOXICITY IS ASSOCIATED WITH AGE AND BODY MASS INDEX IN NOPHO- AML min Erik Loeffen The Netherlands 8 min Ditte Juel A Løhmann Denmark Expert opinion abstracts 16-1-O and 16-2-O 12 min Aminah Jatoi USA Patient Care Introduction to care coordination 1 min Sam Ahmedzai United Kingdom Abstract 26-1-O Abstract 26-6-O CARE COORDINATION EXPERIENCE OF PATIENTS WITH COLORECTAL CANCER: A POPULATION BASED STUDY PATIENT SATISFACTION WITH CANCER-RELATED CARE: LANGUAGE- BASED DIFFERENTIAL ITEM FUNCTIONING. 8 min Ivana Durcinoska Australia 8 min Jean-Pierre Pascal USA Expert opinion abstracts 12 min Sam Ahmedzai United Kingdom Closure 1 min Sam Ahmedzai United Kingdom

51 1 POSTER DISCUSSION SESSION

52 POSTER DISCUSSION 1 CHAIRMEN AND EXPERTS: Jean Klastersky (Belgium) and Mario Dicato (Luxembourg) ROOM CAPACITY: Medium TIME: Friday 08:00-08:45 DURATION OF SESSION: 45 min Febrile neutropenia Introduction febrile neutropenia 1 min Jean Klastersky Belgium Abstract 13-2-O Abstract 13-3-O Abstract 13-4-O Practical Application of a Febrile Neutropenia Pre-Printed Order /Algorithm Incorporating the MASCC Index within a Large Regional Emergency Department ASSESSMENT OF A NOMOGRAM FOR PREDICTING SERIOUS COMPLICATIONS IN PATIENTS FROM THE UNIVERSITY OF SALAMANCA HOSPITAL FEBRILE NEUTROPENIA REGISTRY NORTHERN IRELAND'S EXPERIENCE OF IMPROVING INITIAL NEUTROPENIC SEPSIS MANAGEMENT THROUGH A MULTIDISCIPLINARY INTEGRATED CARE PATHWAY 3 min Lee Ann Martin Canada 3 min Ignacio Matos Spain 3 min Caroline Forde United Kingdom Discussion abstracts 13-2-O, 13-3-O and 13-4-O 12 min Jean Klastersky Belgium Anemia and thrombosis Introduction anemia and thrombosis 1 min Mario Dicato Luxembourg Abstract 08-1-O Abstract 26-4-O TRAJECTORY OF HEMOGLOBIN LEVEL DURING TREATMENT OF SELECTED MYELOSUPPRESSIVE CHEMOTHERAPY REGIMENS FOR BREAST CANCER LEANING UPON INTERNATIONAL DIRECTIVES FOR OPTIMIZATION: ANEMIA 3 min Chun Chao USA 3 min V Launay-Vacher France Abstract 21-1-O VENOUS THROMBOLISM IN CANCER- A PROSPECTIVE STUDY 3 min Aruna Alahari Dhir India Discussions posters 08-1-O, 26-4-O and 21-1-O 12 min Mario Dicato Luxembourg Closure 1 min Mario Dicato Luxembourg

53 IN ADDITION 5 SATELLITE SYMPOSIA AND ONE SPONSORED MEET THE EXPERT SESSION (NOT PART OF THE SCIENTIFIC PROGRAM)